Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 10:24 AM ET

Biotechnology

Company Overview of NGM Biopharmaceuticals, Inc.

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, discovers and develops transformational biologics for the treatment of cardio-metabolic diseases, hepatic diseases, and cancers. It offers NGM282, a phase 2 clinical development products that is used for the treatment of gastric bypass surgery on metabolic and bile acid-related diseases. The company also develops novel drug candidates for the treatment of Type 2 diabetes and obesity. In addition, it offers various drug discovery programs that include enteroendocrine cells, beta-cell regeneration, and intestinal microbiome programs. The company has strategic partnerships with MedImmune/AstraZeneca, Daiichi Sankyo, and JDRF. NGM Biopha...

630 Gateway Boulevard

South San Francisco, CA 94080-7014

United States

Founded in 2007

Phone:

650-243-5555

Fax:

650-583-1646

Key Executives for NGM Biopharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 55
President
Age: 42
Founder, Chief Scientific Officer and Director
Age: 52
Chief Financial Officer
Chief Operating Officer and Vice President
Compensation as of Fiscal Year 2015.

NGM Biopharmaceuticals, Inc. Key Developments

NGM Biopharmaceuticals, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM

NGM Biopharmaceuticals, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Jeff Jonker, President.

NGM Biopharmaceuticals, Inc. Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282

NGM Biopharmaceuticals, Inc. reported positive results from a Phase 2 trial of NGM282 in patients with primary biliary cirrhosis (PBC). NGM282, an engineered protein variant of the human hormone FGF19, demonstrated statistically significant, dose-dependent and clinically meaningful reductions in alkaline phosphatase (ALP), a primary indicator of disease activity, as well as substantial reductions in 7-Hydroxy-4-cholesten-3-one (C4), a marker of bile acid synthesis. These data suggested that NGM282 is a potent regulator of bile acid synthesis. The study was a double blind, placebo-controlled trial in 45 patients randomized 1:1:1 to daily injections of 0.3 mg or 3 mg doses of NGM282 or placebo. Study subjects had a confirmed PBC diagnosis with an inadequate response to ursodeoxycholic acid (UDCA), the current standard of care, defined as an elevated ALP level greater than 1.67 times the upper limit of normal while on therapeutic doses of UDCA for at least 12 months. All subjects continued with UDCA treatment during the study. Patients with pruritus, hyperlipidemia and other comorbidities commonly seen in PBC were allowed to enroll in the study. Data from the trial demonstrated a statistically significant and clinically meaningful percentage reduction in ALP from baseline to day 28 in both NGM282 treatment arms (0.3 mg = -15.8%, p-value = 0.009; 3 mg = -19.2%, p-value = 0.003). Significant reductions of other key markers of liver injury, such as ALT and AST, were also observed for both NGM282 treatment groups. Importantly, NGM282 did not exacerbate pruritus, which is a symptom frequently experienced by many PBC patients that substantially impacts quality of life. More than 50% of study subjects had pruritus at baseline, which was balanced across the three groups. All subjects with pruritus at baseline treated with 3 mg of NGM282 had either an improvement or no worsening of their pruritus during the study. Two subjects without pruritus at baseline, one in each treatment arm, presented with mild, transient pruritus during the study period. However, the overall study assessment demonstrated that there was no significant evidence of drug-induced pruritus in any study arm. NGM282 had a favorable safety and tolerability profile with no identified safety signals. Most adverse events were mild, with a single serious adverse event during the study period that was deemed unrelated to treatment by the investigator. The most common adverse events were mild headache and mild lower gastrointestinal (GI) symptoms (predominantly diarrhea and loose stools). The lower GI symptoms were observed in 21% of the 0.3 mg and 43% of the 3 mg cohorts, compared to 13% of the placebo group. Mild injection site reactions (predominantly erythema or redness) were also observed more frequently with NGM282. There was no evidence of an immunogenic response to NGM282 during or after the treatment period. All lipid parameters and triglycerides remained stable during the treatment period.

NGM Biopharmaceuticals Announces Management Appointments

NGM Biopharmaceuticals, Inc. announced that Jeff Jonker has been named President and David Woodhouse, Ph.D., has joined the company as Chief Financial Officer, effective immediately. Prior to joining NGM, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma and Theravance, Inc. He previously served as the Chief Business Officer of Satori Pharmaceuticals and the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals, prior to its acquisition by Celgene. Dr. Woodhouse joins NGM from Goldman Sachs, where he was Managing Director and Co-Head of U.S. Biotechnology Investment Banking. As a member of Goldman's healthcare investment banking group for nearly 13 years in the New York and San Francisco offices, Dr. Woodhouse's responsibilities included corporate finance and mergers and acquisitions (M&A) advice for the biotechnology, specialty pharma and diagnostics industries.

Similar Private Companies By Industry

Company Name Region
On Target Laboratories, LLC United States
Heller Biotech International, Inc. United States
Giant Funding Corp. United States
Vector Medical Technologies, Inc. United States
Humagen Fertility Diagnostics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 23, 2015
--
Private Placement
October 9, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NGM Biopharmaceuticals, Inc., please visit www.ngmbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.